Michael Schatz
University of California, San Diego
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Michael Schatz.
The New England Journal of Medicine | 2011
Robert S. Zeiger; David T. Mauger; Leonard B. Bacharier; Theresa W. Guilbert; Fernando D. Martinez; Robert F. Lemanske; Robert C. Strunk; Ronina A. Covar; Stanley J. Szefler; Susan J. Boehmer; Daniel J. Jackson; Christine A. Sorkness; James E. Gern; H. William Kelly; Noah J. Friedman; Michael Mellon; Michael Schatz; Wayne Morgan; Vernon M. Chinchilli; Hengameh H. Raissy; Elizabeth Bade; Jonathan Malka-Rais; Avraham Beigelman; Lynn M. Taussig
BACKGROUND Daily inhaled glucocorticoids are recommended for young children at risk for asthma exacerbations, as indicated by a positive value on the modified asthma predictive index (API) and an exacerbation in the preceding year, but concern remains about daily adherence and effects on growth. We compared daily therapy with intermittent therapy. METHODS We studied 278 children between the ages of 12 and 53 months who had positive values on the modified API, recurrent wheezing episodes, and at least one exacerbation in the previous year but a low degree of impairment. Children were randomly assigned to receive a budesonide inhalation suspension for 1 year as either an intermittent high-dose regimen (1 mg twice daily for 7 days, starting early during a predefined respiratory tract illness) or a daily low-dose regimen (0.5 mg nightly) with corresponding placebos. The primary outcome was the frequency of exacerbations requiring oral glucocorticoid therapy. RESULTS The daily regimen of budesonide did not differ significantly from the intermittent regimen with respect to the frequency of exacerbations, with a rate per patient-year for the daily regimen of 0.97 (95% confidence interval [CI], 0.76 to 1.22) versus a rate of 0.95 (95% CI, 0.75 to 1.20) for the intermittent regimen (relative rate in the intermittent-regimen group, 0.99; 95% CI, 0.71 to 1.35; P=0.60). There were also no significant between-group differences in several other measures of asthma severity, including the time to the first exacerbation, or adverse events. The mean exposure to budesonide was 104 mg less with the intermittent regimen than with the daily regimen. CONCLUSIONS A daily low-dose regimen of budesonide was not superior to an intermittent high-dose regimen in reducing asthma exacerbations. Daily administration led to greater exposure to the drug at 1 year. (Funded by the National Heart, Lung, and Blood Institute and others; MIST ClinicalTrials.gov number, NCT00675584.).
Archive | 1998
Michael Schatz; Robert S. Zeiger; Henry N. Claman
The Journal of Allergy and Clinical Immunology | 2000
Robert S. Zeiger; Michael Schatz
Archive | 2002
Eric Macy; Michael Schatz; Robert S. Zeiger
Medical Clinics of North America | 1981
Robert S. Zeiger; Michael Schatz
Middleton's Allergy (Eighth Edition) | 2014
Michael Schatz; Robert S. Zeiger; Reuben Falkoff; Christina D. Chambers; Eric Macy; Michael Mellon
Proceedings of the American Thoracic Society | 2012
Michael Schatz; Gary S. Rachelefsky; Jerry A. Krishnan
Journal of Asthma | 1983
Robert S. Zeiger; Michael Schatz
/data/revues/00916749/v131i2/S0091674912016909/ | 2013
Eli O. Meltzer; Michael Schatz; Robert A. Nathan; Cindy Garris; Richard H. Stanford; Mark Kosinski
/data/revues/00916749/unassign/S0091674913015546/ | 2013
Michael Schatz; Jin-Wen Y. Hsu; Robert S. Zeiger; Wansu Chen; Alejandro Dorenbaum; Bradley E. Chipps; Tmirah Haselkorn